Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

5.580 +0.230 (+4.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 305,712
Open 5.390
Bid (Size) 5.580 (1,500)
Ask (Size) 5.590 (200)
Prev. Close 5.350
Today's Range 5.350 - 5.650
52wk Range 1.000 - 6.910
Shares Outstanding 21,928,452
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire

Performance

YTD
+402.7%
+402.7%
1 Month
+26.5%
+26.5%
3 Month
+15.1%
+15.1%
6 Month
+398.2%
+398.2%
1 Year
+431.4%
+431.4%

More News

Read More
AN2 Therapeutics Inc (NASDAQ:ANTX) Pipeline Progress Outshines Slight Q1 Earnings Miss ↗
Via Chartmill
News headline image
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Top stock movements in today's session. ↗
Via Chartmill
News headline image
AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? ↗
Via Benzinga
News headline image
ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
Via AB Newswire
News headline image
ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally? ↗
Via Stocktwits
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
AN2 Therapeutics Announces $40 Million Private Placement Financing
From AN2 Therapeutics, Inc.
Via Business Wire
Here are the top movers in Friday's session. ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is AN2 Therapeutics, Inc. - Common Stock publicly traded?
Yes, AN2 Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does AN2 Therapeutics, Inc. - Common Stock trade on?
AN2 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AN2 Therapeutics, Inc. - Common Stock?
The ticker symbol for AN2 Therapeutics, Inc. - Common Stock is ANTX on the Nasdaq Stock Market
What is the current price of AN2 Therapeutics, Inc. - Common Stock?
The current price of AN2 Therapeutics, Inc. - Common Stock is 5.580
When was AN2 Therapeutics, Inc. - Common Stock last traded?
The last trade of AN2 Therapeutics, Inc. - Common Stock was at 08/03/26 04:00 PM ET
What is the market capitalization of AN2 Therapeutics, Inc. - Common Stock?
The market capitalization of AN2 Therapeutics, Inc. - Common Stock is 122.36M
How many shares of AN2 Therapeutics, Inc. - Common Stock are outstanding?
AN2 Therapeutics, Inc. - Common Stock has 122M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.